Journal
ONCOGENE
Volume 40, Issue 38, Pages 5705-5717Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-021-01976-2
Keywords
-
Funding
- National Science and Technology Major Project [2018ZX10302205, 2019YFC1315702]
- Guangdong Province Key Research and Development Program [2019B020226002]
- Peking University Clinical Scientist Program [BMU2019LCKXJ011]
- National Science Foundation for Young Scientists of China [81802735]
- Beijing Youth Talent Plan [QML20191101]
- 'San Ming' Project of Shenzhen city, China [SZSM201612051]
- Beijing Municipal Science and Technology Commission NOVA Program [2010B033]
Ask authors/readers for more resources
Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer with high mortality rate. Research suggests that HAS may originate from pluripotent precursor cells and has high stemness and methionine cycle activity. Genes involved in the methionine cycle, such as MAT2A and AHCY, are potential targets for HAS treatment.
Hepatoid adenocarcinoma of the stomach (HAS), a rare subtype of gastric cancer (GC), has a low incidence but a high mortality rate. Little is known about the molecular features of HAS. Here we applied whole-exome sequencing (WES) on 58 tumours and the matched normal controls from 54 HAS patients, transcriptome sequencing on 30 HAS tumours, and single-cell RNA sequencing (scRNA-seq) on one HAS tumour. Our results reveal that the adenocarcinomatous component and hepatocellular-like component of the same HAS tumour originate monoclonally, and HAS is likely to initiate from pluripotent precursor cells. HAS has high stemness and high methionine cycle activity compared to classical GC. Two genes in the methionine cycle, MAT2A, and AHCY are potential targets for HAS treatments. We provide the first integrative genomic profiles of HAS, which may facilitate its diagnosis, prognosis, and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available